Journal article
Accelerated partial breast irradiation using a strut-based brachytherapy device: A multi-institutional initial report on acute and late toxicity with greater than 24-month follow-up
Journal of clinical oncology, v 30(27_suppl), pp 149-149
20 Sep 2012
Abstract
149
Background: Accelerated partial breast irradiation (APBI) is commonly used in early-stage breast cancer. The SAVI Collaborative Research Group is a multi-institutional group created to study outcomes in patients who received APBI utilizing strut-based brachytherapy. This analysis reports the acute and late toxicities for patients with greater than 2-year follow-up (F/U) from this study. Methods: 904 APBI patients (ductal carcinoma in situ [n=267] or invasive breast cancer [n=637]), received HDR brachytherapy (34 Gy in 10 fractions) using the SAVI device (Cianna Medical). Patients with dosimetry and documented follow-up were evaluated within 6 weeks of treatment for early adverse events (AEs), and at 1 year, 2 years, and beyond for late AEs. Dosimetric parameters were evaluated with respect to toxicity and will be presented. Results: In 212 patients (median age 62.9 years, range 40-88) all with follow-up greater than 24 months, the median tumor size was 12mm. As of last follow-up (>24 months) cumulative rates of erythema and hyperpigmentation of grade 2 or higher were 1.4% and 0.5%. The incidence of grade 2 or higher telangiectasia, seroma and fat necrosis were 2.8%, 2.8%, and 0.5% respectively. Conclusions: Adverse events for APBI with SAVI are low in incidence, low in grade and compare favorably to other HDR APBI methods.
Metrics
31 Record Views
Details
- Title
- Accelerated partial breast irradiation using a strut-based brachytherapy device: A multi-institutional initial report on acute and late toxicity with greater than 24-month follow-up
- Creators
- Jon F. Strasser - Christiana Care Health SystemDayee Jacob - Helen F. Graham Cancer Center - Christiana Care Health System, Newark, DEChristoper D. Koprowski - Helen F. Graham Cancer Center - Christiana Care Health System, Newark, DEDeanna J. Attai - Center for Breast Care, Burbank, CAErnest Butler - Schiffler Cancer Center, Wheeling, WVSteven E. Finkelstein - 21st Century Oncology, Scottsdale, AZBen Han - South Florida Radiation Oncology, LLC, Boynton Beach, FLRobert Hong - Virginia Hospital Center, Arlington, VALydia T. Komarnicky - Drexel University College of Medicine, Philadelphia, PARobert R. Kuske - Arizona Breast Cancer Specialists, Scottsdale, AZMaureen Lyden - Biostat Inc., Tampa, FLSudha B. Mahalingam - The Christ Hospital Cancer Center, Cincinatti, OHConstantine Mantz - 21st Century Oncology, Fort Myers, FLSerban Morcovescu - Texas Oncology, Denton, TXStephen S. Nigh - Northwest Community Hospital Cancer Services, Arlington Heights, ILKerri Perry - Kerri Perry, MD, Denton, TXJondavid Pollock - Schiffler Cancer Center, Wheeling, WVJay E. Reiff - Drexel UniversityDaniel Scanderbeg - University of California, San Diego, La Jolla, CACatheryn M. Yashar - University of California, San Diego Moores Cancer Center, La Jolla, CA
- Publication Details
- Journal of clinical oncology, v 30(27_suppl), pp 149-149
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine); [Retired Faculty]
- Web of Science ID
- WOS:000208892500146
- Other Identifier
- 991019168593404721
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Oncology